Gigi Hadid Puts California Girl Aesthetic Into Havaianas Collaboration
Gigi Hadid x Havaianas Collab: NYC Launch Event
Fun fact: When flip flops were invented and patented by Havaianas in 1962, the rubberized shoes were perfect for the South American country's beach lifestyle (hello, The Girl from Ipanema). Its design was based on the Japanese Nori shoe, which was made from straw. Over 60 years later, the easy-to-wear shoes once associated with Brazil's poorer working class have become the de rigueur summer sandals.
NEW YORK, NEW YORK - MAY 28: Gigi Hadid attends the Gigi Hadid X Havaianas launch party at Altro ... More Paradiso on May 28, 2025 in New York City. (Photo by TheStewartofNY/GC Images)
Helping to elevate these humble and affordable shoes has been a slew of brand collaborations that range from Dolce & Gabbana, Manolo Blahnik, and Valentino to Saint Laurent and Disney. Celebrities such as Naomi Campbell, Arizona Muse, and Barbie Ferreira have also teamed up to create capsule collections. For summer 2025, the Brazilian brand has teamed up with Supermodel and Havaianas brand ambassador Gigi Hadid, who has infused styles with a 'California Dreamin" vibe.
Carlyne Cerf de Dudzeele, Gigi Hadid, Olivia Palermo at the Gigi Hadid x Havaianas Collab: NYC ... More Launch Event
Hadid creative directed the six-style capsule collection infused with sunset-inspired prints and color scheme—think orange, pink, and blues ombré effects—on the brand's Top and Slim Square style flip flops that infuse the squishy sandals with a dose of fashion. To promote the offering, which launches in the US in June, a photo campaign that channels a 1940s/50s pin-up vibe and features the self-proclaimed flip-flop lounging in a hammock at a Hollywood set-worthy beach.
To celebrate, the Brazil-founded rubber sandal maker threw a party in downtown Manhattan, attempting to bring the beach to the city with a rooftop fete at Altro Paradiso in Soho. The party channeled the sandy coasts of Rio de Janeiro, complete with palm leaves, tropical flowers, branded coconut shells, pearlized seashell cocktail glasses, customized anklets by Susan Alexandra's charm collection, and a sunset-infused orange glow everywhere.
Flip-flops from the Gigi Hadid X Havaianas collection.
The trendy eatery's vast rooftop boasts a beautiful west-side Manhattan sunset, and the aim was to give guests such as Olivia Palermo and Carlyne Cerf de Dudzeele a front-row view. However, this being New York lately, the weather had another plan. The rain was non-stop on party day. Thus, the event was moved inside. This didn't stop Hadid from turning it out in a charming Marc Jacobs cream dress with chunky jewel accents and a 50s bob hairdo while sporting the orange color of the sandals. After all, every New Yorker knows that in a summer rain, the de facto shoe is a rubber flip-flop, preferably Havaianas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Drug maker Indivior to abandon London stock market for the US
Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2 billion. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The LSE faced the largest exodus of companies since the global financial crisis in 2024, according to EY analysis. There were 88 companies to delist or transfer their primary listing from the main market – the most since 2009. At the same time, the LSE struggled to attract as many new companies to fill the gaps – with 18 new listings in total last year. Nevertheless, Indivior's exit, which will take effect from July 25, comes as Valterra Platinum makes its debut on the London market. Anglo American spun off its platinum business into the new entity, which has become the world's most valuable producer of the metal. Valterra will have its secondary listing on the LSE, with its primary on the Johannesburg Stock Exchange. Duncan Wanblad, Anglo American's chief executive, said: 'Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path – it's an outstanding business and team and I have every confidence that Valterra Platinum will thrive as a leader in the global platinum group metals industry.' Sign in to access your portfolio
Forbes
19 minutes ago
- Forbes
China Accuses US Of Violating Trade Pact—Rejects Trump's Allegation
Chinese authorities on Monday accused the U.S. of violating a recent trade pact that both agreed to in Geneva last month, as they dismissed President Donald Trump's allegation about Beijing breaching the agreement, a move that could signal a further escalation in trade tensions between the two countries, which could potentially jeopardize last month's tariff truce. China's Commerce Ministry accused the U.S. of violating a trade deal agreed in Geneva by imposing ... More additional chip restrictions and canceling Chinese student visas. In a press briefing, a Chinese Commerce Ministry spokesperson dismissed Trump's comments accusing China of violating the agreement, saying Beijing has worked 'to strictly implement and actively safeguard the Geneva deal.' The spokesperson noted that China had acted in accordance with the deal to cancel or suspend 'relevant tariffs and non-tariff measures' it had taken as retaliation against the U.S. government's reciprocal tariffs. The spokesperson then accused the U.S. of introducing ' a number of discriminatory restrictive measures against China' after the talks, citing expanded export controls on AI chips and other chip-building technology. The official also criticized the U.S. government's crackdown on Chinese student visas, saying these actions violated the consensus reached between Trump and Chinese President Xi Jinping in a phone call on January 17. The spokesperson then warned that if the U.S. continues to take actions that damage China, Beijing will 'take resolute and forceful measures to safeguard its legitimate rights and interests.' In a post on his Truth Social platform on Friday, Trump said: 'China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' without specifying how it had done so. The president then signalled that the U.S. may retaliate against this alleged non-compliance, saying: 'So much for being Mr. NICE GUY!' In his post, the president claimed his tariffs had put China in 'grave economic danger' and he made a 'FAST DEAL' in Geneva, 'in order to save them from what I thought was going to be a very bad situation.'
Yahoo
19 minutes ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
